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Abstract: The development of radiolabeled antibodies against CD20 has facilitated targeted 
treatment of follicular lymphoma (FL). By using 90Y-ibritumomab tiuxetan (Zevalin®), a radio-
nuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab) is brought 
into the vicinity of lymphoma cells. By the so-called cross-fire effect, this beta emitter has the 
capacity to destroy not only the lymphoma cells having bound the antibody, but also neighboring 
lymphoma cells. Currently this antibody is licensed in the European Union for use in relapsed 
or refractory FL. It is anticipated that this drug will also be approved for use as consolidation 
therapy after successful first-line treatment. Here we first will review the published literature 
supporting the use of   90Y-ibritumomab tiuxetan in the aforementioned indications and emerg-
ing data showing applicability of ibritumomab tiuxetan as sole first-line therapy for FL, as well 
as in the transplant setting. Possible strategies of incorporating ibritumomab tiuxetan into the 
treatment algorithm of FL are discussed.
Keywords: follicular lymphoma, 90Y-ibritumomab tiuxetan
Introduction
Follicular lymphoma (FL) is the most common indolent subtype and accounts 
for almost a quarter of non-Hodgkin lymphomas (NHL). The course of disease is 
characterized by a response to initial treatment, followed by multiple relapses. Although 
long-term survival has been seen in localized disease treated with involved field radio-
therapy with curative intent, FL is incurable with conventional chemotherapy.1 The 
main impact on survival occurred with the introduction of immunotherapy over the last 
10 years.2 Large randomized clinical studies confirmed the benefit of adding the anti-
CD20 monoclonal antibody rituximab to combination chemotherapy regimes with 
highly significant improvement in progression-free (PFS) and even overall survival 
(OS).3–6 A helpful clinical advance has been the development of the FL international 
prognostic index (FLIPI).7 The FLIPI stratifies patients into risk groups. Based on 
five prognostic factors (age, Ann Arbor Stage, hemoglobin level, number of nodes 
involved and serum LDH level) three risk groups were defined. Low (0–1 risk factor), 
intermediate (2 risk factors) and high (3 risk factors) with 10-year overall survival 
rates of 70.7%, 50.9% and 35.5%, respectively.
Dose intensified consolidation with myeloablative conditioning followed by 
autologous stem cell rescue also leads to an improvement in PFS,8 although this approach 
is only feasibly in younger patients and is associated with higher treatment related 
morbidity and a remarkable risk of secondary malignancies. In a trial of the German Low OncoTargets and Therapy 2009:2 200
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Grade Lymphoma Study Group, secondary hematological 
malignancies were observed in 5 out of 195 patients with 
indolent lymphoma after high-dose chemotherapy, yielding 
an estimated risk of secondary hematological malignancies 
after autologous stem cell transplantation of 3.8%.9 Radioim-
muntherapy (RIT) represents another therapeutic approach 
that allows targeted delivery of a therapeutic dose of radiation 
to tumors at multiple sites in disseminated disease. Currently 
the only radiolabeled antibodies approved for treatment of 
follicular NHL are iodine-131-tositumomab (131I-T, Bexxar®; 
GlaxoSmithKline, Research Triangle Park, NC, USA), which 
is not approved within the European Union (EU) and yttrium-
90-ibritumomab tiuxetan (90Y-IT, Zevalin®; Bayer Schering 
Pharma AG, Berlin, Germany). Both 131I-T and 90Y-IT are 
directed against the CD20 antigen. Radiolabeled immuno-
therapy (RIT) is an established treatment option for second 
relapse or later and 90Y-IT has recently obtained a positive 
opinion of European Medicines Agency (EMEA) about the 
use as consolidation therapy after first-line treatment.
Ibritumomab tiuxetan (Zevalin®)
The radioisotope 90-yttrium (90Y) is linked to the monoclonal 
anti-CD20 antibody ibritumomab by the chelator tiuxetan. 
90Y is a high energy pure beta emitter (2.3 MeV) with 
a physical half-life of 64 hours. More than 90% of the 
emitted radiation is absorbed within 5 mm. This path-length 
corresponds to a diameter of 100 to 200 cells,10 thus allowing 
highly targeted delivery of radiation without a need for patient 
isolation or shielding. Radiation induces cellular damage in 
both, the targeted lymphoma cells and neighboring cells, a 
phenomenon referred to as crossfire or bystander effect, and 
might be effective even in case of poorly vascularized tumors 
and those with heterogeneous antigen expression.11
90Y-IT is currently approved for the treatment of adult 
patients with rituximab-relapsed or refractory CD20-positive 
follicular B-cell NHL in the European Union. Another radio-
labeled anti-CD20 antibody (131I-tositumomab) is approved in 
the United States. Although there are differences in applica-
tion and pharmacokinetics, the efficacy of both radiolabeled 
antibodies seems to be comparable in this indication.
Treatment schedule includes infusion of 250 mg/m² 
rituximab on day 1 and 8 followed by the therapeutic dose of 
90Y-IT on day 8 as intravenous push over 10 minutes.
Rituximab pretreatment is given to improve the biodis-
tribution of the radionuclide and to reduce binding to CD20 
on normal circulating B-cells and B-cells in bone-marrow 
and spleen.12,13 Because 90Y is a pure beta emitter, indium-IT 
was used as a surrogate and chelated to ibritumomab tiuxetan 
for studying biodistribution and biological clearance, using 
gamma camera imaging as part of the registration studies. 
The first rituximab infusion was followed by an application of 
5 mCi of 111In-IT for the purpose of imaging. Gamma camera 
scans were performed within 24 to 48 hours. The dosimetry 
studies showed that the application of 90Y-IT results in a 
minimal radiation exposure of non-targeted organs, but it failed 
to demonstrate a significant correlation between biodistribution 
of the radioactive antibody and hematological toxicity.14 This 
lack of correlation has led to the approval of 90Y-IT within the 
European Union without the necessity for imaging studies.
Recommendations for ibritumomab 
tiuxetan use
A phase I/II trial incorporating a comparison of two doses of 
unlabeled antibody showed an improvement of biodistribu-
tion of the radioimmunoconjugate after pretreatment with 
rituximab at a dose of 250 mg/m². Higher doses did not further 
improve the biodistribution of  111In-IT. For increasing 90Y-IT 
doses, myelotoxicity was found as dose limiting toxicity, 
and the maximum tolerated dose (MTD) was determined to 
be 0.4 mCi/kg (or 14.8 MBq/kg) for patients with platelet 
count over 150,000/µL and 0.3 mCi/kg (or 11.1 MBq/kg) 
for patients with mild thrombocytopenia (baseline platelet 
count 150,000/µL but 100,000/µL).12 Another trial 
confirmed the safe treatment with 90Y-IT in patients with mild 
thrombocytopenia at a dose of 0.3 mCi/kg.15 Patients with 
an increased risk of hematological toxicity or impaired bone 
marrow reserve should be excluded from treatment. Exclusion 
criteria are a 25% infiltration of the bone marrow with 
lymphoma cells, prior radiation therapy to 25% of marrow 
area and baseline platelet count 100,000/µL or neutrophil 
count 1500/µL. Despite initial concerns, preliminary data 
suggest that patients can be safely treated without a significant 
dose reduction of 90Y-IT after myeloablative chemotherapy.16
In an early phase I/II study,17 18 patients with recurrent 
B-cell lymphoma were treated with  90Y-IT at doses 
between 13.5 and 50 mCi. Doses up to 40 mCi were not 
myeloablative; however, 2 patients treated at the 50 mCi level 
required stem cell support. This pivotal report also included 
111In-IT imaging studies. It was shown that preadministration 
of unlabeled antibody resulted in an improved biodistribution 
of the radiolabeled antibody with increased visualization of 
known sites of disease and reduced uptake by non-targeted 
organs (spleen, bone-marrow). In the absence of rituximab 
pretreatment, only 18% of known sites of disease were 
imaged. Rituximab administration at a dose of 1mg/kg body 
weight before 111In-IT imaging studies resulted in detection OncoTargets and Therapy 2009:2 201
90Y-ibritumomab tiuxetan for follicular lymphoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of 56% of known disease sites, with further improvement 
achieved (imaging of 92% of known disease sites) at higher 
rituximab doses (2.5 mg/kg body weight). Also the intensity 
of imaging tended to be higher following infusion of the 
unlabeled antibody.
It seems that the radioimmunoconjugate is confronted 
by a considerable antigenic sink, ie,by binding to CD20 on 
normal B-cells or nonspecific uptake by cells of the reticulo-
endothelial system expressing Fc receptors. Splenomegaly and 
high tumor burden (bulky disease) adversely affect imaging in 
biodistribution studies, especially in the absence of rituximab 
pretreatment. Nevertheless, it has been argued recently that 
the routine rituximab application before RIT might also 
compromise the effectiveness of treatment by competition 
for binding sites on tumor cells.18 This view is supported by a 
preclinical lymphoma xenograft model, where indeed larger 
doses seem to block subsequent binding of the radiolabeled 
anti-CD20 monoclonal antibody.19 However, in a recently 
performed phase I/II study, higher pretreatment rituximab 
doses (4 × 375 mg/m2 weekly) achieved a beneficial effect in 
terms of increasing the half-life of the radioimmunoconjugate. 
Also, neither clinical efficacy of RIT did appear to be com-
promised, nor toxicity increased.20 Similarly, in 2 trials using 
rituximab + chemotherapy combination therapy before 90Y-IT 
application,28,29 a significant rate of conversion from partial 
response (PR) to complete response (CR) was observed, again 
indicating that prior rituximab therapy does not hamper RIT.
Patient management
Since 2002, 90Y-IT is approved in the United States (US) 
for patients with CD20+FL or transformed B-cell NHL, 
refractory to or relapsed after rituximab. Within the European 
Union (EU) the license is restricted to rituximab-relapsed or 
refractory CD20+FL. 90Y-IT is the only therapy approved for 
the use after rituximab failure in the EU.
90Y-IT is contraindicated in patients with known hyper-
sensitivity to mouse antibodies or chelating agents (such as 
tiuxetan), as well as during pregnancy and lactation. Patients 
should be advised to wash their hands thoroughly after 
urination, to clean up spilled urine and body fluids immedi-
ately and to use condoms for sexual intercourse for at least 
one week after RIT as well as an effective contraception for 
up to a whole year after treatment.
Safety/tolerability/toxicity of ibritumomab 
tiuxetan
An integrated safety analysis for 349 patients treated with 
90Y-IT in 5 separate multicenter clinical trials showed 
that the treatment with  90Y-IT in an outpatient setting is 
well tolerated.21 Although 80% of patients reported non-
hematologic adverse events (AEs), the majority of those 
AEs were mild or moderate and most frequently asthenia, 
nausea and chills were reported. Only 11% of all patients 
had grade 3 or 4 of non-hematological toxicity. The primary 
hematological toxicity was reversible myelosuppression 
which typically developed by week four to six, reached nadir 
at week seven to nine and recovered within 1 to 4 weeks. 
This pattern of myelosuppression differs from that experi-
enced with myelosuppressive chemotherapy regimes which 
usually have a nadir at day eight to fourteen with recovery 
by day twenty-one. Neutropenia grade 1–2 occurred in 40%, 
grade 3 and 4 in 60% of all patients, respectively. Ninety 
percent of patients with grade 3–4 neutropenia recovered 
to 1000/µL within 12 weeks after RIT. Thrombocytopenia 
grade 1–2 and grade 3–4 were observed in 37% and 63% of 
patients and 89% of patients with grade 3 and 4 thrombocy-
topenia recovered to 50,000/µL during the 12 week period. 
Grade 3 and grade 4 anemia occurred in 13% and 4% of all 
patients. Of 211 patients, 20% received red blood cell transfu-
sions and 22% received platelet transfusions. Patients with 
any involvement of bone marrow had a significant greater 
incidence of grade 4 hematological toxicity and incidence 
of severe thrombocytopenia and neutropenia increased 
with increasing lymphoma bone marrow involvement at 
baseline, underscoring the importance of excluding patients 
with 25% bone marrow infiltration. Despite the incidence 
of grade 4 neutropenia in approximately one third of the 
patients, the rate of severe infections is low. Infections of 
all severity occurred in 29% of patients. The incidence of 
hospitalization was 7% including only 6 cases (2%) of febrile 
neutropenia. The number of prior chemotherapy regimes 
was not associated with longer median duration of grade 
3–4 anemia, thrombocytopenia or neutropenia, although 
patients who had more than two prior chemotherapies were 
twice as likely to develop severe thrombocytopenia. Toxicity 
data from patients less then 65 years of age were compared 
with those from patients of 65 years and older. The analysis 
of safety in the geriatric subset revealed no significant age-
related effects in non-hematological AEs or hematological 
toxicity. The incidence of secondary myelodysplastic syn-
drome (MDS) and acute leukemia (AML) was 2.5% in a 
retrospective analysis of 746 patients with NHL treated with 
90Y-IT between 1996 and 2002. Patients had been treated 
with a median of 3 previous treatment lines (4 in 42% of 
patients) before receiving 90Y-IT. MDS or AML were diag-
nosed at a median of 1.9 years (range 0.4 to 6.3 years) after OncoTargets and Therapy 2009:2 202
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RIT. This incidence is comparable with the incidence in a 
similar patient population having been treated with alkylating 
agents and other chemotherapy regimens, suggesting that 
there is not a significant additional risk following  90Y-IT 
treatment.22
With the use of murine and chimeric antibodies there 
is a risk of immunogenicity that could potentially hamper 
effectiveness of repeated monoclonal antibody administra-
tion.23 However less then 2% of all patient developed human 
anti-mouse antibodies (HAMA) or human anti-chimeric 
antibodies (HACA) and almost no patient with HAMA or 
HACA experienced unusual AEs, despite a case report of 
anaphylaxis after 90Y-IT application with high HAMA blood 
levels recently published by Jankowitz et al.24
relapsed/refractory follicular lymphoma
Long-term efficacy data of an early phase I/II trial have 
been reported.25 Sixty-five % (n = 33) of patients had FL 
and overall response rate (ORR) was 85% in this subgroup 
(CR/Cru [unconfirmed CR] 57%, PR 27%). Median time to 
progression (TTP) was 9.3 months for all patients (including 
24% of patients with diffuse-large B-cell lymphoma and 
11% of patients with nonfollicular low grade lymphoma 
and mantle cell lymphoma). Patients achieving CR/CRu 
with the 0.4 mCi/kg dose (n = 13) had a median TTP of 
28.3 months, patients achieving a CR (n = 8) a median 
TTP of 45.0 months, underscoring the potential of 90Y-IT 
to achieve long-term remissions even in heavily pretreated 
patients (median 2 prior regimens, range 1 to 7). Duration 
of response over 3 years was observed in 24% of responders 
and response duration 5 years was noted in 14%.
A randomized phase III trial including 143 rituximab-
naïve patients with relapsed or refractory low grade, fol-
licular, or transformed lymphoma then compared  90Y-IT 
(0.4 mCi/kg, single dose) with rituximab (375 mg/m² once 
weekly for 4 weeks). Seventy-nine % of enrolled patients 
had FL, 12% other types of low-grade lymphoma and 
9% transformed lymphoma. The response rates favored 
90Y-IT (ORR 80% vs 56%, P = 0.002; CR rate 30% vs 16%, 
P = 0.04).13 The time to progression (TTP) and the duration 
of response were not significantly different, although patients 
with FL treated with 90Y-IT showed a trend towards longer 
TTP (12.6 months vs 10.2 months, P = 0.062) and achieved 
more often responses lasting longer than 6 months (74% 
vs 52%, P = 0.019) compared to patients in the rituximab 
control group. Quality of life analysis showed a significant 
improvement of physical, social, emotional and functional 
well-being in the RIT arm.
In another trial, 90Y-IT was evaluated as treatment for 
patients with rituximab-refractory FL. Rituximab-refractory 
disease was defined as either failure of treatment with 
the unlabeled antibody or progression 6 months after 
rituximab treatment. Fifty-four patients with FL after a 
median of 4 prior treatments were enrolled. Bulky disease 
was present in 74% of patients. An ORR of 74% and a CR 
rate of 15% were observed and median TTP was 6.8 months 
for all patients and 8.7 months for responders.11
In two reports,26,27 data from the 4 registration trials11,13,15,25 
of  90Y-IT were analyzed retrospectively. Long-term responses 
(TTP  12 months) were noted in 37% of 211 patients treated 
in these trials. The achievement of CR/CRu seemed to be the 
best predictor for achievement of long-term response. Other 
predictors for durable remissions in a stepwise multivariate 
logistic regression analysis were nonbulky disease (5 cm) 
and stage I or II disease at the time of RIT. At a median 
follow-up of 53.5 months the median duration of response 
was 28.1 months and the median TTP was 29.3 months for 
long-term responders. The estimated OS at 5 years was 53% 
for all patients treated with 90Y-IT and 81% for long-term 
responders.26
63 patients were treated with 90Y-IT after their first relapse 
and 148 patients after 2 or more therapies. Patients receiving 
90Y-IT after first relapse had a greater ORR (86% vs 72%, 
P = 0.05).27 Also, the CR/CRu rate was significantly higher 
(49% vs 28%, P = 0.004) and the median TTP was longer 
(12.6 vs 7.9 months, P = 0.025) in the group that received 
90Y-IT as second-line therapy. In patients with FL, the differ-
ence was even more pronounced with a trend towards greater 
efficacy than in the overall patient population (Cr/CRu: 51% 
vs 28% P = 0.009; TTP: 15.4 vs 9.2 months, P = 0.026).
The results of the pivotal studies evaluating  90Y-IT in 
relapsed/refractory FL are summarized in Table 1.
Consolidation treatment
In a phase II study, the efficacy of a short course of 
chemoimmunotherapy (3 cycles of rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisone (R-CHOP) 
followed by  90Y-IT and “extended” rituximab (a single 
additional 4-week course of rituximab at 375 mg/m2, day 1, 
8, 15, 22) as first-line treatment for FL was investigated.28 
Of the 60 patients entering this trial, 55 patients completed 
therapy according to protocol. Patients with FL stage III–IV, 
grade 1–3 were included. Bulky disease was present in 50% 
of patients and 75% of patients were FLIPI high-risk. RIT 
induced grade 3–4 neutropenia occurred in 51% of patients 
and grade 3–4 thrombocytopenia in 44%. Only a single OncoTargets and Therapy 2009:2 203
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patient required hospitalization because of neutropenia. 
For the 55 patients who completed therapy according to 
protocol (R-CHOP→ 90Y-IT→ “extended” rituximab), the 
CR assessed by computed tomography (CT) was 44%, and 
67% assessed by positron emission tomography (PET) after 
R-CHOP and increased to 89% (CT) and 96% (PET) after 
RIT, respectively. PET-scan after 3 cycles of R-CHOP was 
demonstrated to harbor the potential for early prediction of 
treatment failure. A correlation of early PET results with 
treatment outcome has so far only been reported for diffuse-
large B-cell lymphoma and Hodgkin lymphoma. In this 
study, 7 of 18 patients who were PET positive after R-CHOP 
progressed, compared to 3 of 37 patients who were PET 
negative after R-CHOP (P  0.01). On an intent-to-treat 
basis, the PFS and OS at 24 months were 73% and 94.8%, 
for patients completing therapy according to protocol the 
values are 78.4% and 100%.
Similarly, Shipley et al29 observed an improvement of 
CR rates from 28% after a short course of R-CHOP to 67% 
following RIT consolidation. Forty-two untreated patients 
with grade 1–3 FL were included in this study. The PFS 
was 77% at 2 years.
The prospective multicenter phase II FLUMIZ-trial 
aimed to assess the efficacy and safety of fludarabine 
and mitoxantrone plus  90Y-IT in untreated patiens with 
follicular NHL.30 61 patients with stage III or IV, grade 1–2 
untreated follicular NHL were enrolled and treated with oral 
fludarabine and mitoxantrone for six cycles. Patients with at 
least a partial response (PR), platelet counts 100,000/µL, 
neutrophile counts 1500/µL and less then 25% infiltration 
of bone marrow were deemed eligible for consolidation 
therapy with single dose  90Y-IT, according to usual 
application recommendations. Treatment was administered 
on an outpatient-basis 6 to 10 weeks after the last cycle of 
chemotherapy. After 6 cycles of chemotherapy the ORR was 
98% (43 of 61 patients had CR and 17 of 61 patients had PR). 57 
of 61 patients went on to receive RIT. Of the 14 patient in this 
cohort who had PR after initial chemotherapy, 12 obtained CR 
after 90Y-IT. By the end of entire treatment 55 of 57 patients 
achieved CR. 90Y-IT also seemed capable of improving the 
rate of molecular complete remissions, as determined by 
monitoring the Bcl2-IgH rearrangement. With a median follow 
up of 30 months estimated 3-year PFS is 76% and estimated 
3-year OS is 100%. The chemotherapy regime was well 
tolerated and reversible hematological toxicity was the most 
common AE. AEs after 90Y-IT were also mainly hematological 
and transient. 21 of 57 patient required transfusion of either 
red blood cell or platelets or both. Patients with relapsed 
disease underwent second-line treatment (R-CHOP) with good 
hematological tolerance. All these patients completed 6 cycles 
of second-line therapy.
An international, randomized controlled phase III trial 
(First-Line Indolent Trial, FIT) evaluated the safety and 
efficacy of consolidation therapy with a single dose of 
90Y-IT in patients who achieved a PR or better with first-line 
induction therapy. A total of 414 patients with FL stage III 
or IV, grade 1–2 were enrolled31 and primary endpoint was 
PFS. Patients who achieved CR, CRu or PR after first-line 
induction with variable regimens were randomly assigned 
to receive either 90Y-IT (208 patients) or no further therapy 
(control, 206 patients). The most common AEs with 90Y-IT 
were hematological toxicities, which were predictable and 
manageable. Although infectious events were more common 
in the 90Y-IT group, grade 4 infections were rare and only 
Table 1 90Y-iT in relapsed or refractory non-Hodgkin lymphoma
Reference  N  Patients  Response  TTP  Response 
duration
witzig et al12 51 relapsed/refractory CD20 + B-cell low  
and intermediate grade NHL/MCL
Orr 67% 
Cr 26%
12.9 + months 10.8–14.4 months
witzig et al13 143 relapsed/refractory low grade FL  
or transformed NHL
Orr 80% 
Cr 30% 
Cru 4%
15 months (only FL) 14.2–16.7 months 
(only FL)
wiseman et al15 30 relapsed/refractory low grade FL or  
transformed NHL (mild thrombocytopenia)
Orr 83% 
Cr 37% 
Cru 6%
9.4 (all)–12.6 (FL)  
months
11.7 months
witzig, et al11 54 rituximab refractory FL Orr 44% 
Cr 27%
6.8–8.7 (responder) 
months
11.5 months
Abbreviations: CR, complete response; CRu, unconfirmed CR; NHL, non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma; FL, follicular lymphoma; ORR, overall response 
rate;   TTP, time to progression.OncoTargets and Therapy 2009:2 204
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7.4% of patients required hospitalization for infections in 
the RIT arm. After a median observation period of 3.5 years 
the median PFS time was significantly higher in the 90Y-IT 
arm with 36.5 months vs 13.3 months in the control arm 
(P  0.0001). A benefit was seen both for patients in PR 
after induction treatment as well as for patients in CR after 
induction treatment. The final CR/CRu rate was 87.4% after 
consolidation with 90Y-IT compared with 53.3% in the control 
arm. After consolidation with  90Y-IT, 78 of 101 patients 
(77%) with a PR after induction therapy converted to 
CR/CRu. A higher PR-CR conversion rate was noted with 
90Y-IT consolidation as compared to the control arm in nearly 
all subgroups categorized by type of induction treatment. 
Only for the small subgroup of patients receiving rituximab-
containing induction regimens (15% of the total study 
population) this difference was not statistically significant. 
This might be due to the low number of patients in this sub-
group and the even lower number of patients only achieving 
PR after rituximab-containing induction treatment. Also PFS 
was not significantly different between the treatment arms in 
this subgroup, and median PFS times have not been reached in 
either arm at the time of analysis. Thus, while providing clear 
evidence for a beneficial effect of 90Y-IT consolidation after 
chemotherapy-only induction treatment, this study leaves the 
question unanswered if a similar benefit is achieved with RIT 
after a full course of R-chemotherapy induction.
The results of studies using  90Y-IT as consolidation 
treatment for FL are summarized in Table 2.
First-line treatment
90Y-IT was also studied as first-line monotherapy for 
patients with low-grade FL. In a pilot study including 
10 patients an ORR of 100% was observed, with a CR 
rate of 62%32. In this study, maintenance rituximab was 
scheduled at 6-months intervals over 2 years. More recently, 
Carella et al33 reported an ORR of 93% and a CR rate of 
73% using upfront  90Y-IT in a treatment-naïve cohort of 
patients with FL grade 1–2. Fifteen patients were evaluable 
at the time of reporting.
Myeloablative allogeneic 
stem cell transplantation
In Phase I/II trials,  90Y-IT has been incorporated in 
the conditioning regimen before autologous stem cell 
transplantation (see Table 3). Most of these trials included 
mainly patients with aggressive B-cell NHL, except a GELA 
study, which included 77 patients with CD20+ low-grade 
B-cell lymphoma (90% of those FL).34 90Y-IT was given 
at the standard dose of 15 MBq/kg at day -14 combined 
with carmustine, etoposide, cytarabine, and melphalan 
(BEAM) chemotherapy starting at day -7. Median time to 
neutrophil reconstitution was 12 days, as was time to platelet 
reconstitution. Adverse events were not different from those 
expected with a standard conditioning regimen.
Similar results were observed in smaller trials exploring 
90Y-IT in combination with chemotherapy conditioning in 
the transplant setting35–37(see Table 3). In one of these trials, 
escalated doses of 90Y-IT were applied,37 with doses of the 
radioimmunoconjugate calculated to deliver cohort-defined 
radiation-absorbed doses (RADs) to critical organs, ranging 
from 1 to 17 Gy. Escalated doses of   90Y-IT (applied on day -14) 
calculated to achieve a maximum RAD of 15 Gy to the critical 
normal organ could be safely combined with high-dose BEAM 
and autologous stem-cell transplantation, with similar toxicity 
profile as compared to BEAM alone. Severe hepatotoxicity 
occurred in only one patient case, although the liver was the 
critical dose-limiting organ in the majority of patients. Dose-
limiting toxicities were observed at the 17 Gy dose level, 
including pneumonia with sepsis and subsequent organ fail-
ure in one patient, and septic pulmonary emboli related to an 
infected intravenous catheter in a second patient.
In other trials, high-dose RIT was applied without 
chemotherapy before stem-cell infusion (Table 3). In one 
of these studies,38 30 patients with poor-risk, relapsed or 
Table 2 First-line consolidation treatment with 90Y-iT
Reference  Treatment  Patient  
number
CR after  
induction
CR after  
90Y-IT
PFS 
Jacobs et al28 3x r-CHOP → 90Y-iT → 4x r 55 44% 89% 78% at 2 years
Shipley et al29 4x r → 3x r-CHOP or r-CvP → 90Y-iT 42 28% 67% 77% at 2 years
Zinzani et al30 6x FM → 90Y-iT 61 70% 96% 76% at 3 years
Morschhauser et al31 various → 90Y-iT 208 Not reported 87% Median 36.5 months
McLaughlin et al46 4x r-FND → 90Y-iT → r-maintenance 35 Not reported 83% 74% at 3 years
Abbreviations: Cr, complete response; PFS, progression-free survival.OncoTargets and Therapy 2009:2 205
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chemotherapy-refractory B-cell NHL (including 12 patients 
with FL) were treated with  90Y-IT at 2 dose levels 
(0.8 mCi/kg, 1.2 mCi/kg). Stem-cells were given 7 days 
and 14 days after RIT. Only 47% of patients developed 
neutropenia with absolute neutrophil count (ANC) 500/µL 
(grade 4) and the median duration of  grade 4 neutropenia was 
5 days (range 1 to 14) in this subset of patients. The platelet 
count fell to 25,000/µL (grade 4 thrombocytopenia) in 63% 
of patients, and median duration of this complication was 
4 days (range 1 to 14). Infections were registered in 27% of 
patients, with hospitalization required in 10%.
In another trial39 using escalating doses of   90Y-IT 
(0.8, 1.2, 1.5 mCi/kg) before stem cell support, severe infec-
tious complications and hepatotoxicity were noted. One 
patient developed bacterial pneumonia 2 months and herpes 
zoster infection 5 months after 90Y-IT, and another patient 
experienced hepatitis C virus reactivation. Also, one patient 
developed a myelodysplastic syndrome (refractory anemia 
with excess of blasts) 2 years after treatment.
RIT has also been used as part of a reduced intensity 
conditioning regimen for allogeneic stem cell transplantation 
(90Y-IT application on day –14). Thirty-six patients with 
indolent lymphoma (refractory or relapsed; age 34 to 68 years), 
including 15 patients with FL, have so far been treated in a 
phase II study. No additional toxicity was observed due to 
RIT in comparison with previous experience with allogeneic 
transplantation, and stable engraftment has been achieved 
in all patients.40 Shimoni et al41 treated 12 patients with 
advanced chemorefractory NHL at median age 54 years 
using 90Y-IT in the allogeneic transplant setting. Notably, 
a non-relapse mortality of 42% was observed, mainly due 
to acute graft-versus-host disease.
integration of 90Y-iT in the treatment 
algorithm for FL
Currently, there is a strong rationale for using  90Y-IT 
either as consolidation treatment for patients achieving 
a PR or CR after first-line therapy for FL or for relapsed 
disease. This has recently also been pointed out by Otte 
et al.42 The benefit of  90Y-IT as consolidation treatment 
has been shown in a phase III trial for patients receiving 
chemotherapy as first line treatment.31 The subset of 
patients receiving rituximab + chemotherapy induction 
first-line was too small to demonstrate a beneficial effect 
of  90Y-IT consolidation unequivocally, but this issue is 
being addressed in another trial (R-CVP + 90Y-IT vs R-CVP 
alone; trial NCT00384111). Rituximab maintenance after 
successful first-line induction therapy is another emerging 
treatment approach for FL. This strategy was shown to pro-
long PFS after induction therapy with chemotherapy-only 
in the first line setting.43 With R-maintenance (375 mg/m2, 
once per week for 4 weeks, every 6 months for 4 courses) 
a prolongation of PFS from 15.6 months in the observation 
arm to 51.6 months in the rituximab arm was reported, 
results comparable to 90Y-IT consolidation. In the relapsed 
setting, a benefit for rituximab maintenance therapy was 
also noted for patients receiving rituximab as part of their 
induction regimen.44,45 The issue of rituximab maintenance 
therapy after R-chemotherapy has also been addressed 
for the first line setting (MAXIMA trial NCT00430352); 
however, results of this trial are not available yet. Never-
theless, due to the positive results in the relapsed setting, 
rituximab maintenance therapy is often used after R-chemo 
first-line therapy (in the regimen used by Hochster et al, 
or 375 mg/m2 every 3 months over 2 years). The ques-
tion whether a rituximab maintenance strategy or a RIT 
consolidation after R-chemotherapy induction first-line 
should be used or which of these approaches is more 
effective is currently unanswered. It should be noted that 
a combined approach (R-chemotherapy induction followed 
by 90Y-IT consolidation followed by rituximab maintenance 
therapy) has been used successfully in a small study46 in a 
high-risk population of newly diagnosed patients with FL, 
at least demonstrating the feasibility of such approach.
Several studies have now reported that high-dose therapy 
with autologous transplantation can be performed safely in 
Table 3 90Y-iT in the autologous transplant setting
Reference No. patients FL 90Y-IT dose Conditioning chemotherapy
Gisselbrecht et al34 70 15 MBq/kg BeAM
Nademanee et al35 12 rAD 1 Gy vP16/Cyclophosphamide
Krishnan et al36 4 0.4 mCi/kg BeAM
winter et al37 4 rAD 1–17 Gy BeAM
Devizzi et al38 12 0.8 + 1.2 mCi/kg None
Ferrucci et al39 1 0.8–1.5 mCi/kg None
Abbreviations: rAD, radiation-absorbed doses (rADs) to critical organs; FL, follicular lymphomic; BeAM, carmustine, etoposide, cytarabine, and melphalan.OncoTargets and Therapy 2009:2 206
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patients relapsing after 90Y-IT treatment.47,48 Thus it seems 
feasible to withhold high-dose therapy until relapse for 
patients treated with 90Y-IT consolidation. To date, 4 trials on 
autologous transplantation first-line for patients with FL have 
been reported.8,49–51 None of these trials demonstrated an 
improvement of overall survival with the high-dose approach 
(not even with an extended follow-up of median 9 years in 
the French trial), although in 3 out of these 4 trials a benefit in 
terms of response rates and PFS was seen. It was concluded 
that high-dose therapy with autologous transplantation should 
preferably be applied in the relapsed setting. An upfront high-
dose strategy is less attractive due to a high rate of secondary 
malignancies as well as the safety and efficacy of autologous 
transplantation performed at the time of relapse. However, 
when using 90Y-IT consolidation therapy, caution should be 
taken to collect autologous stem-cells for patients suitable for 
high-dose therapy before 90Y-IT application, as RIT might 
compromise stem-cell yield.
90Y-IT was also shown to be effective as sole first-line 
therapy for FL in 2 small trials (without preceding induction 
chemotherapy). Currently, however, data are limited on 
the durability of responses. As 90Y-IT is similarly safe and 
effective in older as in younger patients,52 such approach 
could be valuable in the older age group, where poor 
tolerability of chemotherapy is of concern. Notably, also 
retreatment with 90Y-IT (ie, 2 courses of RIT) seemed feasible 
and effective in a retrospective analysis of a small cohort of 
patients with B-cell NHL.53
In the relapsed setting,  90Y-IT proved capable of 
achieving long-term remissions. However, in a randomized 
phase III trial RIT did not yield a significant improvement of 
TTP or duration of response as compared to a short course 
of rituximab treatment, despite better efficacy in terms of 
response rates. A high tumor burden (presence of bulky 
disease, Stage III or IV disease) seems to adversely affect 
long term outcome after 90Y-IT, giving a rationale for using 
induction chemotherapy prior to RIT in the relapsed setting, 
in an approach analogous to the first line consolidation 
strategy. Currently several phase II trials are ongoing using 
chemo (immuno-) therapy followed by RIT for relapsed 
disease, but no results have been reported so far. Following 
such strategy, it could be expected that an improvement of 
CR/CRu rates can be achieved, which again are an important 
determinant of durability of response. For the same reasons 
it might be preferable to use 90Y-IT in the first relapse rather 
than later. Higher response rates and better PFS can be 
expected if  90Y-IT is used early in the course of disease. 
Also, there was concern to use 90Y-IT in patients relapsed 
after multiple treatment regimens including autologous 
transplantation because of potentially fatal hematological 
toxicity. Although recently this approach was reported to 
be safe,54,55 hematological side effects seem to be more 
pronounced as compared to first or second line RIT. Another 
report recommended a lower dose (0.2 mCi/kg) of 90Y-IT for 
patients relapsing after autologous transplantation.56 Thus, we 
currently favor using 90Y-IT in the first relapse (eventually 
after debulking chemotherapy), withholding high-dose 
chemotherapy with autologous transplantation for the second 
relapse for eligible patients. A third option for patients with 
relapse of FL would be a rituximab-chemotherapy combina-
tion, followed by rituximab maintenance therapy. As these 
treatment strategies have not been compared in a randomized 
fashion, individual patient and disease characteristics are the 
main determinants for the choice of therapy. Specifically, the 
type of first-line therapy administered and the disease-free 
interval achieved should be considered when deciding about 
the optimal second-line treatment.
Another promising treatment strategy is integration 
of RIT in the conditioning protocol before autologous 
transplantation. In a phase II trial, the standard dose of 
90Y-IT (0.4 mCi/kg) could be added to BEAM chemotherapy 
before transfusion of stem cells seemingly without additional 
toxicity as compared to standard chemotherapy conditioning. 
However, currently it is unknown whether such strategy is 
capable of achieving an improvement of results as compared 
to conventional conditioning regimens. A phase III study 
enrolling patients in chemosensitive relapse of B-cell NHL 
(diffuse large cell or transformed FL) is planned to answer 
this question (trial NCT00463463). Escalated doses of 90Y-IT 
without myeloablative chemotherapy have also been studied 
as conditioning regimen. This approach might be especially 
attractive for patients who are otherwise not good candidates 
for a standard transplantation strategy due to older age or 
co-morbidities. An European study suggested that a novel 
transplant regimen using up to 1.2 mCi/kg 90Y-IT followed by 
a double stem-cell reinfusion can be performed safely with-
out dosimetry. However, in two other studies on autologous 
transplantation a wide range of RADs to critical organs was 
observed when using a weight based dose selection, implying 
that dosimetry is important when 90Y-IT doses are applied 
above the standard dose of 0.4 mCi/kg. Notably, in one of 
these studies significant toxicity was observed using escalated 
90Y-IT as sole conditioning regimen before autologous trans-
plantation, especially at the highest dose level of 1.5 mCi/kg. 
Further data are thus necessary before such regimens can be 
incorporated into routine clinical transplantation practice.OncoTargets and Therapy 2009:2 207
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In conclusion, we can expect that the role of RIT in the 
treatment of patients with FL will be of growing importance. 
Results of ongoing and future studies will help to further 
clarify the best strategy for incorporating RIT into the treat-
ment algorithm of these patients.
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